Tularik Report issue

For profit Phase 2 Phase 3
Founded: South San Francisco CA United States (1991)
Status: Acquired by Amgen (2004)

Organization Overview

First Clinical Trial
2000
NCT00022243
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

batabulin (2 trials)

doxorubicin (Doxil) (1 trial)

Drugs in Phase 2 Trials (3)

folic acid (1 trial)

lometrexol (1 trial)

t-900607 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Esophageal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Ovarian Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5